Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Implant-based multiparameter telemonitoring of patients with heart failure (IN-TIME): a randomised controlled trial

G. Hindricks, M. Taborsky, M. Glikson, U. Heinrich, B. Schumacher, A. Katz, J. Brachmann, T. Lewalter, A. Goette, M. Block, J. Kautzner, S. Sack, D. Husser, C. Piorkowski, P. Søgaard, . ,

. 2014 ; 384 (9943) : 583-90.

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc14074114
E-zdroje Online Plný text

NLK ProQuest Central od 1992-01-04 do Před 3 měsíci
Nursing & Allied Health Database (ProQuest) od 1992-01-04 do Před 3 měsíci
Health & Medicine (ProQuest) od 1992-01-04 do Před 3 měsíci
Family Health Database (ProQuest) od 1992-01-04 do Před 3 měsíci
Psychology Database (ProQuest) od 1992-01-04 do Před 3 měsíci
Health Management Database (ProQuest) od 1992-01-04 do Před 3 měsíci
Public Health Database (ProQuest) od 1992-01-04 do Před 3 měsíci

Odkazy

PubMed 25131977
DOI 10.1016/s0140-6736(14)61176-4
Knihovny.cz E-zdroje

BACKGROUND: An increasing number of patients with heart failure receive implantable cardioverter-defibrillators (ICDs) or cardiac resynchronisation defibrillators (CRT-Ds) with telemonitoring function. Early detection of worsening heart failure, or upstream factors predisposing to worsening heart failure, by implant-based telemonitoring might enable pre-emptive intervention and improve outcomes, but the evidence is weak. We investigated this possibility in IN-TIME, a clinical trial. METHODS: We did this randomised, controlled trial at 36 tertiary clinical centres and hospitals in Australia, Europe, and Israel. We enrolled patients with chronic heart failure, NYHA class II-III symptoms, ejection fraction of no more than 35%, optimal drug treatment, no permanent atrial fibrillation, and a recent dual-chamber ICD or CRT-D implantation. After a 1 month run-in phase, patients were randomly assigned (1:1) to either automatic, daily, implant-based, multiparameter telemonitoring in addition to standard care or standard care without telemonitoring. Investigators were not masked to treatment allocation. Patients were masked to allocation unless they were contacted because of telemonitoring findings. Follow-up was 1 year. The primary outcome measure was a composite clinical score combining all-cause death, overnight hospital admission for heart failure, change in NYHA class, and change in patient global self-assessment, for the intention-to-treat population. The trial is registered with ClinicalTrials.gov, number NCT00538356. FINDINGS: We enrolled 716 patients, of whom 664 were randomly assigned (333 to telemonitoring, 331 to control). Mean age was 65·5 years and mean ejection fraction was 26%. 285 (43%) of patients had NYHA functional class II and 378 (57%) had NYHA class III. Most patients received CRT-Ds (390; 58·7%). At 1 year, 63 (18·9%) of 333 patients in the telemonitoring group versus 90 (27·2%) of 331 in the control group (p=0·013) had worsened composite score (odds ratio 0·63, 95% CI 0·43-0·90). Ten versus 27 patients died during follow-up. INTERPRETATION: Automatic, daily, implant-based, multiparameter telemonitoring can significantly improve clinical outcomes for patients with heart failure. Such telemonitoring is feasible and should be used in clinical practice. FUNDING: Biotronik SE & Co. KG.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc14074114
003      
CZ-PrNML
005      
20141009093744.0
007      
ta
008      
141006s2014 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/S0140-6736(14)61176-4 $2 doi
035    __
$a (PubMed)25131977
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Hindricks, Gerhard $u Herzzentrum Leipzig, Leipzig, Germany. Electronic address: gerhard.hindricks@medizin.uni-leipzig.de.
245    10
$a Implant-based multiparameter telemonitoring of patients with heart failure (IN-TIME): a randomised controlled trial / $c G. Hindricks, M. Taborsky, M. Glikson, U. Heinrich, B. Schumacher, A. Katz, J. Brachmann, T. Lewalter, A. Goette, M. Block, J. Kautzner, S. Sack, D. Husser, C. Piorkowski, P. Søgaard, . ,
520    9_
$a BACKGROUND: An increasing number of patients with heart failure receive implantable cardioverter-defibrillators (ICDs) or cardiac resynchronisation defibrillators (CRT-Ds) with telemonitoring function. Early detection of worsening heart failure, or upstream factors predisposing to worsening heart failure, by implant-based telemonitoring might enable pre-emptive intervention and improve outcomes, but the evidence is weak. We investigated this possibility in IN-TIME, a clinical trial. METHODS: We did this randomised, controlled trial at 36 tertiary clinical centres and hospitals in Australia, Europe, and Israel. We enrolled patients with chronic heart failure, NYHA class II-III symptoms, ejection fraction of no more than 35%, optimal drug treatment, no permanent atrial fibrillation, and a recent dual-chamber ICD or CRT-D implantation. After a 1 month run-in phase, patients were randomly assigned (1:1) to either automatic, daily, implant-based, multiparameter telemonitoring in addition to standard care or standard care without telemonitoring. Investigators were not masked to treatment allocation. Patients were masked to allocation unless they were contacted because of telemonitoring findings. Follow-up was 1 year. The primary outcome measure was a composite clinical score combining all-cause death, overnight hospital admission for heart failure, change in NYHA class, and change in patient global self-assessment, for the intention-to-treat population. The trial is registered with ClinicalTrials.gov, number NCT00538356. FINDINGS: We enrolled 716 patients, of whom 664 were randomly assigned (333 to telemonitoring, 331 to control). Mean age was 65·5 years and mean ejection fraction was 26%. 285 (43%) of patients had NYHA functional class II and 378 (57%) had NYHA class III. Most patients received CRT-Ds (390; 58·7%). At 1 year, 63 (18·9%) of 333 patients in the telemonitoring group versus 90 (27·2%) of 331 in the control group (p=0·013) had worsened composite score (odds ratio 0·63, 95% CI 0·43-0·90). Ten versus 27 patients died during follow-up. INTERPRETATION: Automatic, daily, implant-based, multiparameter telemonitoring can significantly improve clinical outcomes for patients with heart failure. Such telemonitoring is feasible and should be used in clinical practice. FUNDING: Biotronik SE & Co. KG.
650    _2
$a senioři $7 D000368
650    12
$a defibrilátory implantabilní $7 D017147
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a srdeční selhání $x patofyziologie $x terapie $7 D006333
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ambulantní monitorování $x přístrojové vybavení $7 D018670
650    _2
$a telemedicína $x metody $7 D017216
650    _2
$a výsledek terapie $7 D016896
651    _2
$a Austrálie $7 D001315
651    _2
$a Evropa $7 D005060
651    _2
$a Izrael $7 D007557
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Taborsky, Milos $u Department of Internal Medicine I-Cardiology, Faculty of Medicine and Dentistry, Olomouc, Czech Republic.
700    1_
$a Glikson, Michael $u Chaim Sheba Medical Center, Tel-Hashomer, Israel.
700    1_
$a Heinrich, Ullus $u Praxis Dr Heinrich, Nordhausen, Germany.
700    1_
$a Schumacher, Burghard $u Herz-und Gefäßklinikum GmbH Bad Neustadt, Bad Neustadt, Germany.
700    1_
$a Katz, Amos $u Barzilai Medical Center, Ashkelon, Israel.
700    1_
$a Brachmann, Johannes $u Klinikum Coburg GmbH, Coburg, Germany.
700    1_
$a Lewalter, Thorsten $u Isar Herzzentrum, Munich, Germany.
700    1_
$a Goette, Andreas $u St Vincenz Krankenhaus GmbH, Paderborn, Germany.
700    1_
$a Block, Michael $u Klinik Augustinum, Munich, Germany.
700    1_
$a Kautzner, Josef $u Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Sack, Stefan $u Klinikum Schwabing, Munich, Germany.
700    1_
$a Husser, Daniela $u Herzzentrum Leipzig, Leipzig, Germany.
700    1_
$a Piorkowski, Christopher $u Herzzentrum Leipzig, Leipzig, Germany.
700    1_
$a Søgaard, Peter $u Heart Centre and Clinical Institute, Aalborg University Hospital, Aalborg, Denmark.
700    1_
$a ,
773    0_
$w MED00010161 $t Lancet $x 1474-547X $g Roč. 384, č. 9943 (2014), s. 583-90
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25131977 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20141006 $b ABA008
991    __
$a 20141009094133 $b ABA008
999    __
$a ok $b bmc $g 1041997 $s 873026
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 384 $c 9943 $d 583-90 $i 1474-547X $m Lancet $n Lancet $x MED00010161
LZP    __
$a Pubmed-20141006

Najít záznam

Citační ukazatele

Možnosti archivace